Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CHF)
Sales 2016 50 939 M
EBIT 2016 18 097 M
Net income 2016 11 566 M
Debt 2016 10 221 M
Yield 2016 3,53%
Sales 2017 53 619 M
EBIT 2017 19 583 M
Net income 2017 12 733 M
Debt 2017 4 697 M
Yield 2017 3,77%
P/E ratio 2016 17,61
P/E ratio 2017 15,94
EV / Sales 2016 4,29x
EV / Sales 2017 3,98x
Capitalization 208 453 M
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the diagnostics and pharmaceuticals segments.The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The diagnostic segment... 
Sector
Pharmaceuticals
Calendar
06/06 | 01:30amPresentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
04/29 FOUNDATION MEDICINE : Horizon Blue Cross Blue Shield of New Jerseys Chief Medica..
04/29 ROCHE : CHMP recommends EU approval of Roche’s Gazyvaro for people with pr..
04/29 ROCHE : CHMP recommends EU approval for Roche's Avastin in combination with Tarc..
04/29 ROCHE : Diagnostics Operations Assigned Patent
04/29DJAstraZeneca's Investment Eats Into Profit
04/28 Federal Contracts Awarded to Companies in Indiana (April 28)
04/28 Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation
04/28DJAbbVie to Buy Cancer-Drug Maker for $5.8 Billion
More news
Sector news : Pharmaceuticals - NEC
04/30 Buffett, Munger slam Valeant; drugmaker turned into 'a sewer'
04/30 ABBVIE : Galapagos and AbbVie expand their cystic fibrosis collaboration
04/30 SANOFI : Zealand reports Lyxumia royalty revenue for Q1 2016 and submission by S..
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions